Company Announcement / Press release Archives

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 13 May 2025 at 10.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CEST. The shareholders may exercise their voting rights at the annual general meeting by attending […]

Xspray Pharma re-submits its FDA application

Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application procedure thus runs according to the most recently communicated plan. Within 2-4 weeks, the FDA is expected to announce a new PDUFA date, i.e. the date they […]

Xspray Pharma AB publishes its Annual Report for 2024

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2024. An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma: “In 2024, we finalized the foundation for Xspray Pharma’s transformation from an innovative, research-driven company into a commercial drug company. We have addressed regulatory challenges, conducted market […]

Interim Report Fourth Quarter 2024

October–December 2024, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -82,002 thousand (-54,513) Earnings per share before dilution amounted to SEK -2.36 (-1.85) Cash flow from operating activities amounted to SEK -61,601 thousand (-32,626) Cash flow from investing activities amounted to SEK -19,202 thousand (-20,729) Amounts in parentheses […]

Xspray Pharma reports strong interim data for product candidate XS003 – confirms plan to apply for market approval in H1 2025

Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap™ technology platform and its ability to deliver significant benefits for patients compared to existing PKI drugs. Key findings from interim data: Food interaction and safety: Xspray's […]

New number of shares and votes in Xspray Pharma after rights issue

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued following the rights issue announced on November 6, 2024. The number of outstanding shares and votes has increased by 3,376,266 shares to a total of 37,138,491 shares and the […]

Xspray publishes the final outcome of the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR […]

Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is published

Xspray publishes prospectus relating to the rights issue

Interim Report Third Quarter 2024

July – September 2024, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -82,272 thousand (-38,942) Earnings per share before dilution amounted to SEK -2.44 (-1.59) Cash flow from operating activities amounted to SEK -41,275 thousand (-68,611) Cash flow from investing activities amounted to SEK -9,053 thousand (-14,470) January […]